Drug General Information
Drug ID	D06JHV
Former ID	DIB013320
Drug Name	Flumatinib
Synonyms	HH-GV-678
Drug Type	Small molecular drug
Indication	Chronic myelogenous leukaemia [ICD9: 205.1; ICD10:C92.1]		Phase 2	[525279]
Company	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
Structure		Download 2D MOL 3D MOL
Formula	C29H29F3N8O
Canonical SMILES	FC(F)(c1cc(C(=O)Nc2cnc(c(c2)Nc2nc(ccn2)c2cnccc2)C)ccc1C<br />N1CCN(CC1)C)F
PubChem Compound ID	46848036
Target and Pathway
Target(s)	Proto-oncogene c-Abl	Target Info	Inhibitor	[532541]
KEGG Pathway	ErbB signaling pathway
	Ras signaling pathway
	Cell cycle
	Axon guidance
	Neurotrophin signaling pathway
	Pathogenic Escherichia coli infection
	Shigellosis
	Pathways in cancer
	MicroRNAs in cancer
	Chronic myeloid leukemia
	Viral myocarditis
PANTHER Pathway	Axon guidance mediated by Slit/Robo
Pathway Interaction Database	p73 transcription factor network
	ATM pathway
	Regulation of Telomerase
	Posttranslational regulation of adherens junction stability and dissassembly
	Lissencephaly gene (LIS1) in neuronal migration and development
	PDGFR-beta signaling pathway
	Neurotrophic factor-mediated Trk receptor signaling
	Validated transcriptional targets of TAp63 isoforms
	p53 pathway
	Regulation of retinoblastoma protein
Reactome	Regulation of actin dynamics for phagocytic cup formation
	CDO in myogenesis
	RHO GTPases Activate WASPs and WAVEs
	HDR through Single Strand Annealing (SSA)
	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
	Factors involved in megakaryocyte development and platelet production
WikiPathways	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Fcgamma receptor (FCGR) dependent phagocytosis
	ATM Signaling Pathway
	Retinoblastoma (RB) in Cancer
	Integrated Pancreatic Cancer Pathway
	Pathogenic Escherichia coli infection
	Regulation of Microtubule Cytoskeleton
	Integrated Breast Cancer Pathway
	Signaling by Robo receptor
	Myogenesis
	Factors involved in megakaryocyte development and platelet production
References
Ref 525279	ClinicalTrials.gov (NCT02511340) A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients.
Ref 532541	Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.